Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: A randomized clinical trial. Issue 4 (April 2015)

• Record Type: Journal Article
• Authors: Compare, Debora; Rocco, Alba; Sgamato, Costantino; Coccoli, Pietro; Campo, Salvatore Maria Antonio; Nazionale, Immacolata; Larussa, Tiziana; Luzza, Francesco; Chiodini, Paolo; Nardone, Gerardo
• Is Part Of: Digestive and liver disease. Volume 47:Issue 4(2015)
• Page Start: 273
• Page End: 279
• Publication Date: 2015-04
• Subjects: Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2015.01.004
• Languages: English
• ISSNs: 1590-8658

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <title id="sect0010">Background</title> <p id="spar0005">Proton pump inhibitors may foster intestinal dysbiosis and related bowel symptoms.</p> </sec> <sec> <title id="sect0015">Aim</title> <p id="spar0010">To evaluate the effect of <italic>Lactobacillus paracasei</italic> F19 on bowel symptom onset in patients on long-term proton pump inhibitors.</p> </sec> <sec> <title id="sect0020">Methods</title> <p id="spar0015">In this randomized, double-blind, placebo-controlled study, patients with typical gastroesophageal reflux disease symptoms receiving pantoprazole 40 mg/d for six months were randomly assigned to receive: (A) <italic>Lactobacillus paracasei</italic> F19 bid for three days/week for six months; (B) placebo bid for three days/week for six months; (C) <italic>Lactobacillus paracasei</italic> F19 bid for three days/week for three months and placebo bid for three days/week for the following three months; (D) placebo bid for three days/week for three months and <italic>Lactobacillus paracasei</italic> F19 bid for three days/week for the following three months. Bloating, flatulence, abdominal pain and bowel habit were assessed monthly.</p> </sec> <sec> <title id="sect0025">Results</title> <p id="spar0020">100/312 patients were enrolled. In the parallel groups, the treatment-by-time interaction affected bloating (<italic>p</italic> = 0.015), while <italic>Lactobacillus paracasei</italic> F19 treatment alone affected flatulence (<italic>p</italic> = 0.011). Moreover, the treatment-by-time interaction significantly affected the mean score of bloating (<italic>p</italic> = 0.01) and flatulence (<italic>p</italic> < 0.0001), the mean stool form (<italic>p</italic> = 0.03) and mean stool frequency/week (<italic>p</italic> = 0.016). Analysis of the cross-over groups, limited to the first three months because of carry-over effect, confirmed these results.</p> </sec> <sec> <title id="sect0030">Conclusion</title> <p id="spar0025"> <italic>Lactobacillus paracasei</italic> F19 supplementation prevents bowel symptom onset in patients on long-term proton pump inhibitors.</p> </sec> </abstract>